Abstract
New psychoactive substances in substantive evidence in expert practice of the Department of Forensic Medicine, UJCM in the years 2010–2015
- Chair and Department of Forensic Medicine, Jagiellonian University Medical College, Krakow, Poland
Aim of the study:
Aim of the study was to analyse of 2075 evidences containing new psychoactive substances (NPS).
Material and methods
The prepared samples were identified employing an analytical procedure where the analytes were investigated by gas chromatography-electron impact mass spectrometry (GC-EI-MS) using a created library of mass spectra.
Results
The analysis revealed the following substances in the investigated products: piperazine derivatives (including BZP, MPMP, TFMPP), cathinone derivatives (including: pentedrone, 3-MMC, butylone, 4-MEC), pyrovalerone derivatives (MDPV, naphyrone, α-PVP, α-PVT), synthetic cannabinoids (such as AM-2201, UR-144, XLR-11, JWH073, JWH081, PB-22, AB-CHMINACA). Research conducted in 2010–2015 made it possible to track changes in the composition of investigated preparations.
Conclusions
The following relationships has been shown: number of components decreased and in the end of 2015 dominated preparations with single component; introduction of amendments Act on Preventing Drug Addictionn affect the elimination from the market of one compounds and replacing them by their derivatives; since 2011 on the market of ‘legal highs’ we did not observe occurrence of compounds of piperazine group.
Keywords
new psychoactive substances (NSP), GC-EI-MS, identification
Indexed in
Integrated with
